Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferrolife
- Development stage
- Unknown
- Lead developer
- Maxx Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Ferrolife** is an oral fixed-dose antianemic capsule marketed by Maxx Pharm. Each capsule contains iron(III) hydroxide polymaltose complex equivalent to 120 mg elemental iron, folic acid 1.5 mg, cyanocobalamin 15 micrograms, and zinc sulfate monohydrate 61.8 mg. It is used for treatment and prevention of iron deficiency anemia, including nutritional anemia and iron deficiency associated with pregnancy and lactation. The product supplies iron for hemoglobin synthesis and replenishment of iron stores, while folate and vitamin B12 support erythropoiesis and DNA synthesis. ([maxxpharm.com](https://maxxpharm.com/uploads/enpdf/ferrolife-en.pdf))
- Brand names
- Ferrolife
- Other names
- Ферролайф
Beyond the preview
Go deeper on Ferrolife.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ferrolife.